Here are relevant reports on : infectious-disease-diagnostics-market
-
North America Human Microbiome Market By Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029
The global vaccine adjuvants market, valued at US$0.66 billion in 2023, stood at US$0.70 billion in 2024 and is projected to advance at a resilient CAGR of 6.5% from 2024 to 2029, culminating in a forecasted valuation of US$0.96 billion by the end of the period. Growing awareness about livestock health, increasing the adoption of companion animals and developing of therapeutic vaccines for cancer, allergies, and autoimmune disorders are creating lucrative growth opportunities
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
The global companion diagnostics market is projected to reach USD 11.57 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
US Veterinary Diagnostics Market by Application (Infectious, Bacterial, Endocrine), Technology (Immunodiagnostic, PCR, ELISA, Lateral Flow), Product (Consumables, Instruments), Animal Type (Dog, Cat, Cattle), End User (POC, Veterinary Labs) – Forecast to 2031
The US veterinary diagnostics market, valued at USD2.22 billion in 2025, stood at USD2.41 billion in 2026 and is projected to advance at a resilient CAGR of 9.1% from 2026 to 2031, culminating in a forecasted valuation of USD3.74 billion by the end of the period.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Europe In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Europe in vitro diagnostics (IVD) market, valued at USD 31.43 billion in 2025, stood at USD 33.83 billion in 2026 and is projected to advance at a resilient CAGR of 7.9% from 2026 to 2031, culminating in a forecasted valuation of USD 49.49 billion by the end of the period. Market growth is driven by rising diagnostic test volumes across national healthcare systems, broader adoption of population-based screening programs, and increasing emphasis on standardized disease monitoring.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application (Infectious, Cancer), Technique, Clinical Application, End User- Global Forecast to 2031
The molecular diagnostics market is estimated at USD 21.68 billion in 2026 and is projected to reach USD 32.56 billion by 2031 at a CAGR of 8.5% during the forecast period. The Key Players Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Limited (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030
The global in vitro diagnostics market, valued at USD 101.05 Billion in 2024, stood at USD 109.06 Billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2030, culminating in a forecasted valuation of USD 157.63 Billion by the end of the period. Market growth is primarily fueled by the rising prevalence of chronic and infectious diseases, increasing demand for rapid and accurate diagnostic solutions, and the growing shift toward personalized medicine.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
US In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
US In Vitro Diagnostics market, valued at USD 37.43 billion in 2025, stood at USD 40.15 billion in 2026 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2031, culminating in a forecasted valuation of USD 57.18 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic and infectious diseases, the increasing demand for early and accurate diagnostic testing, the widespread adoption of advanced molecular diagnostic technologies, the growth in point-of-care testing, and continuous innovations in diagnostic instruments and assays.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Asia Pacific in vitro diagnostics market is valued at an estimated USD 29.27 billion in 2026 and is projected to reach USD 45.11 billion by 2031 at a CAGR of 9.0% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher (US), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., (China)., Siemens Healthineers AG (Germany), bioMérieux (France), Illumina, Inc. (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US).
- Published: November 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
